These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9681705)

  • 1. The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity--the experience of the Lombardy Dialysis Registry.
    Locatelli F; Conte F; Marcelli D
    Nephrol Dial Transplant; 1998 Jul; 13(7):1642-4. PubMed ID: 9681705
    [No Abstract]   [Full Text] [Related]  

  • 2. [A hematocrit greater than 36 lessens mortality and hospitalization in hemodialysis].
    Fernández-Gallego J; Gutiérrez C
    Nefrologia; 2003; 23(2):177-8. PubMed ID: 12778885
    [No Abstract]   [Full Text] [Related]  

  • 3. Target haematocrit during erythropoietin treatment in dialysis patients. Which value is 'true-functional haematocrit'?
    Vlassopoulos D; Sonikian M; Dardioti V; Hadjiconstantinou V
    Nephrol Dial Transplant; 1999 May; 14(5):1340-1. PubMed ID: 10344405
    [No Abstract]   [Full Text] [Related]  

  • 4. Erythropoietin treatment for anemia in end-stage renal disease with diabetes mellitus.
    Nakatsuka K; Hino M; Miki T; Nishizawa Y; Tabata T; Inoue T; Morii H
    Diabetes Care; 1990 Nov; 13(11):1130-1. PubMed ID: 2261828
    [No Abstract]   [Full Text] [Related]  

  • 5. Defining a renal anemia management period.
    Besarab A; Levin A
    Am J Kidney Dis; 2000 Dec; 36(6 Suppl 3):S13-23. PubMed ID: 11118154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
    Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
    Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin 1997: a brief update.
    Gahl GM; Eckardt KU
    Perit Dial Int; 1997; 17 Suppl 2():S84-90. PubMed ID: 9163805
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of erythropoietin on cardiovascular diseases.
    Sunder-Plassmann G; Hörl WH
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S20-5. PubMed ID: 11576916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anemia management in patients with chronic renal insufficiency.
    Kausz AT; Obrador GT; Pereira BJ
    Am J Kidney Dis; 2000 Dec; 36(6 Suppl 3):S39-51. PubMed ID: 11118157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy.
    Raine AE
    Lancet; 1988 Jan; 1(8577):97-100. PubMed ID: 2891990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different answer to recombinant human erythropoietin in anephric and non-anephric haemodialyzed patients.
    Buemi M; Allegra A; Aloisi C; Giacobbe MS; Frisina N
    Nephron; 1990; 56(2):218-9. PubMed ID: 2243581
    [No Abstract]   [Full Text] [Related]  

  • 12. Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted model.
    Messana JM; Chuang CC; Turenne M; Wheeler J; Turner J; Sleeman K; Tedeschi P; Hirth R
    Am J Kidney Dis; 2009 Mar; 53(3):503-12. PubMed ID: 19185402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemoglobin concentrations in chronic kidney disease.
    Steinbrook R
    Lancet; 2006 Dec; 368(9554):2191-3. PubMed ID: 17189015
    [No Abstract]   [Full Text] [Related]  

  • 14. Morbidity and mortality reduction associated with the use of erythropoietin.
    Tsakiris D
    Nephron; 2000; 85 Suppl 1():2-8. PubMed ID: 10754421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Erythropoietin treatment in Piedmont and Valle d'Aosta].
    Imarisio P; Biamino E; Bongiorno P; Caligaris F; Demicheli G; Montalcini G; Arnaud A
    Minerva Urol Nefrol; 1991; 43(3):143-5. PubMed ID: 1817336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher haematocrit levels: do they improve patient outcomes, and are they cost effective?
    Collins AJ; Keane WF
    Nephrol Dial Transplant; 1998 Jul; 13(7):1627-9. PubMed ID: 9681700
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of anaemia of progressive renal failure with recombinant human erythropoietin. A preliminary report.
    Salim KA; Salim S; Mathew T
    J Assoc Physicians India; 1992 Jan; 40(1):42-3. PubMed ID: 1634463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anemia and cardiovascular complications: iron and EPO impact.
    Kurtzman NA; Sabatini S
    Miner Electrolyte Metab; 1999; 25(1-2):109-13. PubMed ID: 10207271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.
    Sobota JT
    Contrib Nephrol; 1989; 76():166-78; discussion 212-8. PubMed ID: 2684519
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of erythropoietin in predialysis patients.
    Anderson S
    Am J Kidney Dis; 1991 May; 17(5 Suppl 1):103-6. PubMed ID: 2024665
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.